Cynthia X. Ma, MD, PhD, on Copanlisib, Fulvestrant, and Abemaciclib for HER2-Positive Breast Cancer: New on the Scene

Posted: Friday, June 28, 2024

Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, discusses endocrine resistance in patients with hormone receptor–positive, HER2-negative breast cancer, and how phase I findings on copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib may affect the treatment landscape in the future.

---